GBA3

Cytosolic beta-glucosidase · Q9H227 · GBA3 on Sugi Atlas →

483 patent compounds predicted against GBA3, 252 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Duvoglustat (SCHEMBL2969)	1.00	2/20
Duvoglustat (SCHEMBL142573)	1.00	2/20
Deoxymannojirimycin (SCHEMBL329674)	1.00	2/20
Duvoglustat (SCHEMBL1479364)	1.00	2/20
Duvoglustat (SCHEMBL1527007)	1.00	2/20
Duvoglustat (SCHEMBL1527009)	1.00	2/20
Duvoglustat (SCHEMBL2163281)	1.00	2/20
Duvoglustat (SCHEMBL2434068)	1.00	2/20
Deoxymannojirimycin (SCHEMBL3367857)	1.00	2/20
Deoxymannojirimycin (SCHEMBL4323978)	1.00	2/20
Duvoglustat (SCHEMBL4330678)	1.00	2/20
Duvoglustat (SCHEMBL4619759)	1.00	2/20
Duvoglustat (SCHEMBL8010302)	1.00	2/20
Duvoglustat (SCHEMBL9015606)	1.00	2/20
Duvoglustat (SCHEMBL9290667)	1.00	2/20
Duvoglustat (SCHEMBL9620329)	1.00	2/20
Duvoglustat (SCHEMBL9620331)	1.00	2/20
Duvoglustat (SCHEMBL10028910)	1.00	2/20
Duvoglustat (SCHEMBL12017698)	1.00	2/20
Duvoglustat (SCHEMBL12017699)	1.00	2/20

Clinical trials — most relevant to GBA3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3	PHASE3	COMPLETED
Ambroxol as a Disease-modifying Treatment in GBA-PD	PHASE2	COMPLETED
Ambroxol as a Treatment for Parkinson's Disease Dementia	PHASE2	UNKNOWN
Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease	PHASE2	WITHDRAWN
High-Dose Ambroxol in GBA1-Related Parkinson	PHASE1/PHASE2	UNKNOWN
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease	PHASE1/PHASE2	WITHDRAWN
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension	PHASE2	ACTIVE_NOT_RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	PHASE2	ACTIVE_NOT_RECRUITING
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis	PHASE1	WITHDRAWN
Assessment of Neurological Manifestations in Gaucher Disease Patients	nan	UNKNOWN
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease	nan	COMPLETED
Biomarker Analysis for GBA Associated Parkinson's Disease	nan	UNKNOWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Biomarker for Patients With Fabry Disease (BioFabry)	nan	WITHDRAWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Biomarkers Related to Bone in Pediatric Gaucher Disease	nan	UNKNOWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Early Detection and Follow-Up of Patients With Fabry's Disease	nan	UNKNOWN
Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C	nan	UNKNOWN
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers	nan	COMPLETED
Effect of Migalastat on Cardiac Involvement in Fabry Disease	nan	COMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)	nan	WITHDRAWN
Natural History in Fabry Patients With IVS4+919G>A Mutation	nan	UNKNOWN
Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GBA3 binder may also engage these)

Protein	Name	Similarity
Q5RF65	—	1.000	Q5RF65 →
P97265	—	1.000	P97265 →
Q9FIW4	—	0.995	Q9FIW4 →
Q339X2	—	0.994	Q339X2 →
Q7XKV2	—	0.992	Q7XKV2 →
Q5N863	—	0.992	Q5N863 →
Q7XKV5	—	0.991	Q7XKV5 →
Q75W17	—	0.990	Q75W17 →
P26205	—	0.990	P26205 →
Q0J0N4	—	0.990	Q0J0N4 →
Q9LV33	—	0.990	Q9LV33 →
B8AVF0	—	0.990	B8AVF0 →
Q84YK7	—	0.990	Q84YK7 →
O64882	—	0.990	O64882 →
Q25BW5	—	0.990	Q25BW5 →
Q9LU02	—	0.989	Q9LU02 →
Q9FLU9	—	0.989	Q9FLU9 →
Q8GRX1	—	0.989	Q8GRX1 →
Q3ECS3	—	0.989	Q3ECS3 →
B3H5Q1	—	0.989	B3H5Q1 →
Q7XSK2	—	0.988	Q7XSK2 →
Q7XKV4	—	0.988	Q7XKV4 →
B9FHH2	—	0.988	B9FHH2 →
Q95X01	—	0.987	Q95X01 →
A3C053	—	0.987	A3C053 →
Q9FH03	—	0.987	Q9FH03 →
A0AAW1I778	—	0.987	A0AAW1I778 →
Q0DA21	—	0.987	Q0DA21 →
Q9SLA0	—	0.987	Q9SLA0 →
Q8RZL1	—	0.987	Q8RZL1 →